Cystic fibrosis transmembrane conductance regulator modulating agents

US12421251B2 · kind B2 · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• Alexander Russell Abela · San Diego, US
• Sunny Abraham · San Diego, US
• Corey Anderson · San Diego, US
• Vijayalaksmi Arumugam · San Marcos, US
• Jaclyn Chau · San Diego, US
• Jeremy J. Clemens · San Diego, US
• Thomas Cleveland · San Diego, US
• Timothy A. DWIGHT · Quincy, US
• Bryan A. Frieman · Village of La Jolla, US
• Peter Diederik Jan Grootenhuis · San Diego, US
• Sara S. Hadida Ruah · Village of La Jolla, US
• Yoshihiro ISHIHARA · San Diego, US
• Paul Krenitsky · San Diego, US
• Jason McCartney · Encinitas, US
• Vito Melillo · Escondido, US
• Mark Miller · San Diego, US
• Alina Silina · San Diego, US
• Johnny Uy · San Diego, US
• Jinglan Zhou · San Diego, US

Key dates

• Filing date: Apr 2, 2020
• Grant date: Sep 23, 2025
• Expiry date: Jan 22, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/05
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compound (I), deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing are disclosed. Methods of treating cystic fibrosis using these compounds are also disclosed.